Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
By C. Bulawa, S. Connelly, M. Devit, Lan Wang, Charlotte Weigel, J. Fleming, J. Packman, E. Powers, R. Wiseman, T. Foss and 3 more. Proceedings of the National Academy of Sciences of the United States of America, 2012
702 citations recorded by the source corpus.
Subfields: Molecular Biology, Pharmacology, Physiology
View Paper: https://www.semanticscholar.org/paper/0c70f8ec2ae896ca70d0675a23701711edd94d8b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Arne Elofsson
- Björn Wallner
- Liam J. McGuffin
- David Ménendez Hurtado
- Torsten Schwede
- Yang Zhang
- Badri Adhikari
- Erik Lindahl
Citations in the corpus
- Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis (2019, background): “Tafamidis is the only, so far, FDA approved anti-amyloidogenic drug which is used for the treatment of transthyretin amyloidosis and it acts by arresting transthyretin into homo-tetrameric species (Bulawa et al., 2012).”
- Mass Spectrometry and Machine Learning Reveal Determinants of Client Recognition by Antiamyloid Chaperones (2022, background): “The in fl uence of subunit exchange rate on complex formation was tested experimentally by adding the small organic drug molecule tafamidis, which increases the stability of the tetrameric form of TTR (37).”